July 15, 6:10 AM
Goldman Sachs analyst Salveen Richter upgrades Allogene Therapeutics (NASDAQ:ALLO) from Neutral to Buy and raises the price target from $9 to $32.
May 10, 2:23 PM
RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics’ (NASDAQ: CRSP) sickle cell disease (SCD)/beta-thalassemia…
April 27, 9:17 AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO) received Orphan-drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its drug candidate ALLO-605 for the treatment of patients with multiple myeloma.
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 8:45 AM
Here's a roundup of top developments in the biotech space over the last 24 hours.